Annual and Interim Progress Report Summaries
Principal Investigator: Hagen von Briesen
Project: Global HIV Vaccine Research Cryorepository
Submitted January 31, 2011
The goal of the GHRC project (Global HIV Vaccine Research Cryorepository ) is to establish a state-of-the-art specimen repository where samples and reagents relevant for HIV vaccine development are stored under controlled low-temperature conditions and to provide high quality specimens, tools and procedures, having a direct benefit to the CAVD community. Within the first three years (project phase 1), the HSC has successfully developed these processes, cryoequipment and bioreagents.
The second project phase (August 09 – July 11) has been used to employ, improve and distribute the new cryotechnology platform, to develop new cryomedia and to establish new cooperations, in the field of R&D as well as for technology transfer.
Special attention has been given to the automated production of bioreagents. In November 2010 and July 2011, the automated system to prepare HIV pseudoviruses was validated successfully. Until June 2011, large scale virus stocks of 6 different HIV-Env pseudotyped viruses were produced with the automated system and passed the bridging test. In addition, the production of biomaterials has been extended to the production of Infectious Molecular Clones (IMC) in spring 2011. Up to now, more than 75 different HIVpv and 20 IMCs amounting to 80,000 ml in total were produced manually and automated and distributed globally to the collaboration partners under standardized, optimized as well as validated conditions (according to Good Clinical Laboratory Practice GCLP).
In 2010, the HSC developed two chemically fully defined, endotoxin-free and xeno- and protein free cryomedia. In the past year, we could prove that the PBMC recovery and viability using these new cryomedia was statistical equal or better than a cell cryopreservation with the FBSbased cryomedium. Likewise, the PBMC cryopreservation resulted not only in high cell recovery and viability values, but also in maintenance of T-cell functionality (ELISpot). With 42 material shipments since August 2010 (and 44 in the preceding year), the envisioned HSC service function has been strongly used by the CAVD.
Summing up, the HSC activites could be executed successfully and the newly developed cryoprocedures and cryoequipment have proved their suitability in the daily routine. The outstanding expertise in the field of biobanking/cryostorage is also stressed by the fact that the cryorepository has now been selected to host the human samples of the German Federal Environmental Specimen Bank starting January 2012.